We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sara Tolaney

Sara M. Tolaney MD, MPH

Chief, Division of Breast Oncology; Associate Director, Susan F. Smith Center for Women’s Cancers; Senior Physician, Dana-Farber Cancer Institute, Boston; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Sara Tolaney, MD, MPH is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and is internationally recognized for her research and education leadership in breast cancer. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School.

Dr. Tolaney received her undergraduate degree from Princeton University and her medical degree from UC San Francisco. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained her Masters in Public Health from Harvard School of Public Health.

Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She currently chairs several registration studies in these areas and also leads many investigator-initiated trials. She is the author of over 150 peer-reviewed publications with manuscripts included in many prestigious journals such as the New England Journal, Lancet Oncology, Journal of Clinical Oncology, and JAMA Oncology.

Disclosures

Dr. Tolaney reports the following disclosures: Institutional research funding from Genentech, Eli Lilly, Pfizer, Novartis, Exelixis, Eisai, Bristol Meyers Squibb, Merck, Nanostring, AstraZeneca, Nektar, and Cyclacel.  Advisory services provided to Genentech, Eli Lilly, Pfizer, Novartis, Eisai, Merck, Nanostring, AstraZeneca, Nektar and Puma.

Conflict of Interests: All Research Support goes to Institution

  • AstraZeneca, PI of Study(s); Consultant; Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Lilly, PI of Study(s); Consultant; Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Merck, PI of Study(s); Consultant; Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Nektar, PI of Study(s); Consultant; Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Novartis, PI of Study(s); Consultant; Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Pfizer, PI of Study(s); Consultant; Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Genentech/Roche, PI of Study(s); Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Immunomedics/Gilead, PI of Study(s); Advisory Board, Institutional Research Funds; Honorarium; travel expense reimbursement, Breast Cancer Research
  • Exelixis PI of Study(s), Institutional Research Funds, Breast Cancer Research
  • Bristol-Myers Squibb, PI of Study(s) Consultant; Advisory Board, Institutional Research Funds; honorarium;Breast Cancer Research
  • Eisai, PI of Study(s); Consultant; Advisory Board  Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Nanostring, PI of Study(s); Consultant; Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Puma, Advisory Board, Honorarium; travel expense reimbursement, Breast Cancer Research
  • Cyclacel, PI of Study(s); Institutional Research Funds, Breast Cancer Research
  • Sanofi, Advisory Board, Honorarium, Breast Cancer Research
  • Seattle Genetics, Steering Committee, Honorarium, Breast Cancer Research
  • Odonate –PI of study(s), Institutional research funds; Consulting/Advisory Board, honorarium – Breast Cancer Research
  • Seattle Genetics – PI of study(s), Institutional research funds; Steering Committee/Advisory Board, honorarium – Breast Cancer Research
  • Silverback Therapeutics – Advisory Board, honorarium – Breast Cancer Research
  • G1 Therapeutics – Advisory Board, honorarium – Breast Cancer Research
  • Abbvie – Consulting, honorarium – Breast Cancer Research
  • Athenex – Consulting, honorarium – Breast Cancer Research
  • OncoPep – Advisory Board, honorarium – Breast Cancer Research
  • Daiichi-Sankyo – Advisory Board, honorarium – Breast Cancer Research
  • Kyowa Kirin Pharmaceuticals – Advisory Board, honorarium – Breast Cancer Research
  • Samsung Bioepsis inc. – Advisory Board, honorarium – Breast Cancer Research
  • CytomX – Steering Committee, honorarium – Breast Cancer Research
  • Certara – Advisory Board honorarium, Breast Cancer Research 
  • Mersana– Advisory Board honorarium, Breast Cancer Research
  • Chugai Pharma – Consulting honorarium, Breast Cancer Research
  • Ellipses Pharma– Consulting honorarium, Breast Cancer Research
  • OncoSec – Consulting honorarium, Breast Cancer Research
  • 4D Pharma – Consulting honorarium, Breast Cancer Research
  • Infinity Therapeutics – Consulting honorarium, Breast Cancer Research
  • BeyondSpring Pharma – Consulting honorarium, Breast Cancer Research